Toggle light / dark theme

The flow of granular materials, such as sand and catalytic particles used in chemical reactors, and enables a wide range of natural phenomena, from mudslides to volcanos, as well as a broad array of industrial processes, from pharmaceutical production to carbon capture. While the motion and mixing of granular matter often display striking similarities to liquids, as in moving sand dunes, avalanches, and quicksand, the physics underlying granular flows is not as well-understood as liquid flows.

Now, a recent discovery by Chris Boyce, assistant professor of chemical engineering at Columbia Engineering, explains a new family of gravitational instabilities in granular particles of different densities that are driven by a gas-channeling mechanism not seen in fluids. In collaboration with Energy and Engineering Science Professor Christoph Müller’s group at ETH Zurich, Boyce’s team observed an unexpected Rayleigh-Taylor (R-T)-like instability in which lighter grains rise through heavier grains in the form of “fingers” and “granular bubbles.” R-T instabilities, which are produced by the interactions of two fluids of different densities that do not mix—oil and water, for example—because the lighter fluid pushes aside the heavier one, have not been seen between two dry granular materials.

The study, published today in the Proceedings of the National Academy of Sciences, is the first to demonstrate that “bubbles” of lighter sand form and rise through heavier sand when the two types of sand are subject to vertical vibration and upward gas , similar to the bubbles that form and rise in lava lamps. The team found that, just as air and oil bubbles rise in water because they are lighter than water and do not want to mix with it, bubbles of light sand rise through heavier sand even though two types of sand like to mix.

Read more

Bitcoin spenders can now use the lightning network to shop at e-commerce sites like Amazon.

Crypto payment processing startup Moon announced today that any lightning-enabled wallet can now also be used through Moon’s browser extension. Before this lightning feature, roughly 250 beta users already used Moon to spend crypto on e-commerce sites by connecting the browser extension to exchange accounts like Coinbase.

Moon CEO Ken Kruger told CoinDesk:

Read more

Earlier this year, we launched a new webinar series where our monthly patrons, the Lifespan Heroes, are given the opportunity to join live discussion panels with the researchers who are working on solving aging.

Our April 8th, 2019 episode saw Dr. Mike Lustgarten, Dr. Amy Proal, and Dr. Cosmo Mielke join hosts Dr. Oliver Medvedik and Steve Hill for a discussion about the microbiome and how it relates to aging.

The webinar discusses gut flora and the pro-aging effects of immune system burden, the link between bacterial burden and inflammation, and exercise and nutrition. There was also plenty of discussion about the immediately available practical measures that can improve the gut microbiome and thus control weight and promote health.

Read more

(Natural News) Turkish inventors have created a new building material that is five times stronger than titanium and has the density of wood planks. Most remarkably, this new “Metallic wood” is lighter than titanium and still has the chemical stability of metal for use in manufacturing applications.

The new material is made out of nickel-based cellular materials as small as 17 nano-meters in diameter. These electroplated nickel nano-particles are strategically arranged in struts to maximize their load-bearing strength as a whole. This strategic arrangement of nickel makes the material four times stronger than bulk nickel plating. By tinkering with nano-meter-scale geometry, the inventors can increase the strength and density of the new material. This geometric arrangement of cellular materials is spatially organized and repeated to generate the new “Metallic wood” material. This geometric nano-meter engineering feat produces a very dense material, like that of wood. The inventors have even made the material as dense as water (1,000?kg/m3).

Read more

Background: The medical agent #MK615 is produced from #JapaneseApricot and contains a number of cyclic triterpenes. Antitumor activity of MK615 and its additive effect when combined with gemcitabine in pancreatic cancer cell line. MIAPaCa-2 was previously reported by our group. The objective of this phase I trial was to evaluate safety and feasibility of combined MK615 and gemcitabine therapy in patients with advanced or metastatic pancreatic cancer.

Conclusions: Combined MK615 and gemcitabine therapy was well-tolerated and showed antitumor activity in patients previously treated without gemcitabine or untreated patients with advanced or metastatic pancreatic cancer. Currently, we are planning phase II trials for elderly or frail people.


510

Background: The medical agent MK615 is produced from Japanese apricot and contains a number of cyclic triterpenes. Antitumor activity of MK615 and its additive effect when combined with gemcitabine in pancreatic cancer cell line. MIAPaCa-2 was previously reported by our group. The objective of this phase I trial was to evaluate safety and feasibility of combined MK615 and gemcitabine therapy in patients with advanced or metastatic pancreatic cancer. Methods: Patients with untreated pancreatic cancer or those who underwent chemotherapy without gemcitabine were enrolled. Gemcitabine was infused at 1000 mg/m2 over 30 minutes once weekly for 3 weeks of each 28-day treatment cycle. Three packets of MK615 were orally administered daily during each 28-day treatment cycle, until any discontinuation criteria were met. If severe toxicity occurred, dose was reduced. Results: All five patients enrolled were evaluable for toxicity and response. Median age was 72 (54−79) years. Three patients had performance status (PS) 0, one had PS 1, and one PS 2. Three of five patients had been treated with chemotherapy; two with FOLFIRINOX and one with S-1. One of five patients treated had grade 4 neutropenia and two were administered granulocyte-colony stimulating factor. No patient had febrile neutropenia or adverse event leading to death. Relative dose intensity was 96.6% and 69.8% for MK615 and gemcitabine, respectively. No patients had objective response (complete response + partial response), while 2 of 5 patients (40%) had disease control (objective response + stable disease). Conclusions: Combined MK615 and gemcitabine therapy was well-tolerated and showed antitumor activity in patients previously treated without gemcitabine or untreated patients with advanced or metastatic pancreatic cancer. Currently, we are planning phase II trials for elderly or frail people.